A “similar, but weaker" association was observed for angiotensinogen II receptor blockers. 

Nearly half of all adults in the United States have high blood pressure, according to the American Heart Association.

This is believed to be the first randomized clinical trial focused on treating AAAs with an angiotensin receptor blocker.

The role of ACE inhibitors and ARBs in the treatment of COVID-19 has been a key topic for researchers since the pandemic began. This latest research represents a significant update for clinicians. 

The study's authors tracked 450 patients with uncontrolled high blood pressure.

Researchers tracked more than 3,300 older patients for three years, performing clinical assessments every six months.